Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / DPLO - Lawsuit for Investors in NYSE: DPLO Shares Against Diplomat Pharmacy Inc Announced by Shareholders Foundation


DPLO - Lawsuit for Investors in NYSE: DPLO Shares Against Diplomat Pharmacy Inc Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / March 4, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NYSE: DPLO shares.

Investors, who purchased shares of Diplomat Pharmacy Inc (NYSE: DPLO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On February 22, 2019, Diplomat Pharmacy Inc announced it would be postponing the release of its fourth quarter and full-year 2018 financial results because it will need to record a non-cash impairment charge related to its PBM business. More specifically, Diplomat Pharmacy Inc disclosed the "charge is expected to be equal to a significant portion of the PBM's Goodwill and Definite-lived intangible assets, which total approximately $630 million as of December 31, 2018, prior to impairment charges." Diplomat Pharmacy Inc also withdrew its preliminary 2019 full-year outlook provided in January.

The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Diplomat Pharmacy Inc had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017, that consequently, Diplomat Pharmacy Inc would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions, that due to the foregoing, Diplomat Pharmacy Inc would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior, and that as a result, defendants' statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased Diplomat Pharmacy Inc (NYSE: DPLO) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

Stock Information

Company Name: Diplomat Pharmacy Inc.
Stock Symbol: DPLO
Market: NYSE

Menu

DPLO DPLO Quote DPLO Short DPLO News DPLO Articles DPLO Message Board
Get DPLO Alerts

News, Short Squeeze, Breakout and More Instantly...